Table 1 Main characteristics of the eligible studies
Author | Country | Year | Method | Cases | Controls | Cutoff of | Dilution of antibody | Situation of patients | HR |
|---|---|---|---|---|---|---|---|---|---|
(ALDH1A1+) | (ALDH1A1-) | ALDH1A1 positive | |||||||
Ginestier U.M. [11] | America | 2007 | IHC (TMA) | 24 | 122 | > 5% | BD Biosciences, 1:100 | NA | NA |
Ginestier I.P.C [11] | France | 2007 | IHC (TMA) | 102 | 243 | > 5% | BD Biosciences, 1:100 | NA | 1.76 |
Morimoto [27] | Japan | 2009 | IHC | 21 | 182 | > 0% | BD Biosciences, 1:100 | Treated with surgery | 1.516 |
Charafe-Jauffret [24] | France | 2010 | IHC | 29 | 53 | > 1% | BD Biosciences, 1:50 | IBC, partly treated with surgery | SS, 2.7 |
MFS, 2.72 | |||||||||
Erika Resetkova [29] | America | 2010 | IHC (TMA) | 35 | 159 | > 0% | BD Biosciences, 1:200 | Treated with surgery | NA |
Nalwoga [28] | Uganda | 2010 | IHC (TMA) | 88 | 95 | unclear | BD Biosciences, 1:250 | NA | NA |
Neumeister [19] | America | 2010 | Immunofluorescent assays (AQUA) | 45 | 581 | NA | BD Biosciences, 1:1000 | Treated with surgery | 2.32 |
Pei Yu [23] | China | 2010 | IHC | 18 | 78 | > 0% | Abcam, 1:100 | Treated with surgery | 4.6 |
He Lee [26] | Korea | 2011 | IHC | 12 | 80 | >5% | BD Biosciences, 1:100 | Stage II ~ III, treated with surgery | 4.15 |
Yasuyo [31] | Japan | 2011 | IHC | 54 | 52 | > 0% | BD Biosciences, 1:1000 | TNBC, treated with surgery | 3.696 |
Yoshioka [32] | Japan | 2011 | IHC | 68 | 189 | > 0% | BD Biosciences, 1:1000 | Treated with surgery | OS, 1.93 |
RFS, 1.667 | |||||||||
Mieog [18] | Netherlands | 2012 | IHC | 292 | 195 | > 0% | BD Biosciences, NA | Treated with surgery | RS, 2.36 |
RFS, 1.71 | |||||||||
Nogami [21] | Japan | 2012 | IHC | 7 | 33 | > 5% | BD Biosciences, 1:200 | ALNM+, treated with surgery | 2.26 |
Sakakibara [22] | Japan | 2012 | IHC | 35 | 80 | >5% | BD Biosciences, 1:200 | ALNM+, treated with surgery | 10.044 |
Tan [30] | China, Malay, Indian, Other | 2013 | IHC | 35 | 106 | >10% | Abcam, 1:100 | Treated with surgery | NA |
Dong [25] | China | 2013 | IHC | 56 | 105 | >5% | BD Biosciences, 1:200 | Invasive ductal carcinoma and ALNM+, treated with surgery | OS, 3.309 |
RFS, 2.774 |